What is the standard of care for locally advanced Lung Cancer according to NCCN guidelines

Standard of Care for Locally Advanced Lung Cancer (NCCN Guidelines)

Based on the NCCN Guidelines for Non-Small Cell Lung Cancer, the standard of care for locally advanced lung cancer depends on several factors, including whether the tumor can be surgically removed (resectable) and the patient's overall health.

Key Treatment Approaches

For Resectable Locally Advanced Disease (Stage IIIA)

According to NCCN Guidelines, patients with resectable stage IIIA disease typically have these options:

1. Surgery as Primary Treatment

   • Surgical resection (removal of the tumor and surrounding tissue) remains a primary option
   • Mediastinal lymph node dissection or sampling should be performed during surgery
   • This is often combined with other treatments

2. Neoadjuvant Therapy (Treatment Before Surgery)

   • Systemic therapy (chemotherapy or targeted therapy) given BEFORE surgery to shrink the tumor
   • This approach may improve outcomes for patients with stage IB or higher disease

3. Adjuvant Therapy (Treatment After Surgery)

   • Chemotherapy after surgery to eliminate remaining cancer cells
   • Immunotherapy options like osimertinib (for patients with specific EGFR mutations) or other agents
   • These are given based on specific biomarker findings

For Unresectable Locally Advanced Disease (Stage III)

When surgery is not possible, the NCCN Guidelines recommend:

Definitive Concurrent Chemoradiation (Category 1 - Highest Recommendation)

• Chemotherapy and radiation therapy given at the same time
• Radiation is typically delivered in 30-35 small doses (called fractions) over 6-7 weeks
• Common chemotherapy combinations include:
  • Cisplatin + pemetrexed
  • Cisplatin + etoposide
  • Carboplatin + paclitaxel

Followed by Consolidation Immunotherapy with Durvalumab (Category 1)

• After completing chemoradiation, durvalumab (an immunotherapy drug) is recommended for eligible patients
• This consolidation therapy improves the chance of cure
• Patients must have good performance status (PS 0-1) and no disease progression after chemoradiation

Important Biomarker Testing

Before treatment decisions are made, the NCCN Guidelines emphasize that tissue samples should be tested for:

• EGFR mutations - If present, targeted therapies may be used
• PD-L1 expression - Helps determine which immunotherapy options may work best
• Other driver mutations - Guide treatment selection

Multidisciplinary Evaluation

The NCCN Guidelines stress that a multidisciplinary team evaluation should occur before treatment begins. This team typically includes:

• Thoracic surgeons
• Medical oncologists
• Radiation oncologists
• Pulmonologists

This team approach ensures the most appropriate treatment plan for each patient's specific situation.

Questions to Ask Your Healthcare Team

1. What is my specific stage and is my tumor considered resectable?
2. What biomarker testing has been done on my tumor, and what do those results show?
3. Which treatment approach do you recommend for my case, and why?
4. If surgery is recommended, will I receive chemotherapy before or after surgery?
5. If chemoradiation is recommended, will I be eligible for durvalumab after treatment?
6. What are the potential side effects of my recommended treatment, and how will they be managed?

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.

Source: NCCN Guidelines for Non-Small Cell Lung Cancer, Version 8.2025